GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magle Chemoswed Holding AB (OSTO:MAGLE) » Definitions » Short Interest

Magle Chemoswed Holding AB (OSTO:MAGLE) Short Interest


View and export this data going back to 2020. Start your Free Trial

What is Magle Chemoswed Holding AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Magle Chemoswed Holding AB's Short Interest

For the Biotechnology subindustry, Magle Chemoswed Holding AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Magle Chemoswed Holding AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Magle Chemoswed Holding AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Magle Chemoswed Holding AB's Short Interest falls into.



Magle Chemoswed Holding AB (OSTO:MAGLE) Business Description

Traded in Other Exchanges
N/A
Address
Agneslundsvagen 27, Malmo, SWE, 21215
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.

Magle Chemoswed Holding AB (OSTO:MAGLE) Headlines

No Headlines